Voyager has to have AMBS and the MANF IP on their radar. They have to. They could lock up extremely valuable gene therapy IP. In fact, they could lock up the IP to the most promising growth factor identified (MANF) to approach #3 for treating Parkinson's via gene therapy. They have the cash and other resources to advance it.